|
000
| 03248cam 2200409zi 4500 |
|---|
| 001 | 9.926970 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20231116124145 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230906s2023 onca ob f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 045 | |ax9y2 |
|---|
| 086 | 1 |aHP5-164/2023E-PDF |
|---|
| 245 | 00|aEvaluation of the Public Health Agency of Canada's tuberculosis activities 2015-16 to 2020-21 / |cprepared by the Office of Audit and Evaluation, Health Canada and the Public Health Agency of Canada. |
|---|
| 246 | 17|aEvaluation of the PHAC's tuberculosis activities |
|---|
| 264 | 1|a[Ottawa] : |bHealth Canada and the Public Health Agency of Canada = Santé Canada et l'Agence de la santé publique du Canada, |c2023. |
|---|
| 300 | |a1 online resource (ix, 29 pages) : |bcolour illustrations |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Évaluation des activités de l'Agence de la santé publique du Canada liées à la tuberculose de 2015-2016 à 2020-2021. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"February 2023." |
|---|
| 504 | |aIncludes bibliographical references (pages 26-29). |
|---|
| 520 | |a"This report presents findings from the evaluation of the Public Health Agency of Canada's (PHAC) tuberculosis (TB) activities from April 2015 to March 2021. The evaluation focused on the extent to which PHAC's current approach is appropriate to address the needs of each at-risk population, how scientific and performance information, as well as stakeholders' perspectives, are guiding TB activities and the contribution of PHAC activities to reducing TB rates in Canada. PHAC's TB activities were previously evaluated in 2015. To address these questions, data was collected from a review of literature, internal documents, financial, performance, and scientific data, as well as a comparison of TB strategies and practices with other low-incidence countries, and a case study on the difference in US-Canada incidence rates. Data was analyzed by triangulating information gathered from the different lines of evidence listed above, to increase the reliability and credibility of evaluation findings and conclusions"--Evaluation scope and methodology, page 1. |
|---|
| 610 | 20|aPublic Health Agency of Canada|xEvaluation. |
|---|
| 650 | 0|aTuberculosis|xGovernment policy|zCanada|xEvaluation. |
|---|
| 650 | 0|aTuberculosis|zCanada|xPrevention|xEvaluation. |
|---|
| 650 | 0|aPublic health surveillance|zCanada|xEvaluation. |
|---|
| 710 | 1 |aCanada. |bHealth Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |bOffice of Audit and Evaluation, |eissuing body. |
|---|
| 775 | 08|tÉvaluation des activités de l'Agence de la santé publique du Canada liées à la tuberculose de 2015-2016 à 2020-2021 / |w(CaOODSP)9.930398 |
|---|
| 856 | 40|qPDF|s1.17 MB|uhttps://publications.gc.ca/collections/collection_2023/sc-hc/HP5-164-2023-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/corporate/transparency/corporate-management-reporting/evaluation/phac-tuberculosis-activities-2015-2021.html |
|---|